"Gilead's Trodelvy Disappoints in Lung Cancer Trial, Stock Tumbles"

Gilead Sciences' antibody drug conjugate, Trodelvy, did not significantly extend the lives of patients with metastatic non-small cell lung cancer in a recent study, raising questions about the effectiveness of this type of treatment in oncology. The disappointing results from the Evoke-01 study have implications for investors and oncologists, as antibody drug conjugates are considered a promising area in cancer treatment, combining an antibody with chemotherapy to target cancer cells.